CliffBio
small molecule

CYSTADROPS

CYSTEAMINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYSTADROPS
Active ingredientCYSTEAMINE HYDROCHLORIDE
StrengthEQ 0.37% BASE
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusRX

More from Recordati Rare Diseases Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CYSTADROPS patent cliff — loss of exclusivity — | CliffBio